IMvigor130 clinical trial in patients (pts) with metastatic urothelial carcinoma (mUC): Analysis of upper tract (UT) and lower tract (LT) subgroups.

Maria De Santis,Enrique Grande,Marina Mencinger,Jian-Ri Li,Javier Puente,Kouji Izumi,Jae Lyun Lee,Fatih Kose,Igor Antonyan,Beiying Ding,Himika Patel,Ian D. Davis

IMvigor130 clinical trial in patients (pts) with metastatic urothelial carcinoma (mUC): Analysis of upper tract (UT) and lower tract (LT) subgroups.

2020

Maria De Santis
Enrique Grande
Marina Mencinger
Jian-Ri Li
Javier Puente
Kouji Izumi
Jae Lyun Lee
Fatih Kose
Igor Antonyan
Beiying Ding
Himika Patel
Ian D. Davis

551Background: IMvigor130 demonstrated a statistically significant improvement in PFS in pts receiving atezolizumab (atezo; anti–PD-L1) + platinum-based chemotherapy (plt/gemcitabine [gem]; Arm A) ...

Keywords:

Atezolizumab
Metastatic Urothelial Carcinoma
Gemcitabine
Oncology
Clinical trial
Pathology
Internal medicine
Chemotherapy
Medicine
in patient
upper tract

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations